Last edition
News about "Persevera Phase III study"
Roche Reports Update on PERSEVERA Breast Cancer Trial
Roche reported that the Phase III persevERA study in ER-positive advanced breast cancer did not meet its primary endpoint, though giredestrant plus palbociclib showed numerical improvement and a tolerable safety profile.
Persevera Phase III Study | 09/03/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members